EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation

Francois Pierre Combes iD, Sherwin K B Sy, Ying Fei Li, Sebastien Lorenzo, Kohinoor Dasgupta, Shruti Kapoor, Matthias Hoch, Yu-Yun Ho

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01411-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Francois Pierre Combes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA. francois_pierre.combes@novartis.com. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Asciminib is approved in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) treated with ≥ 2 prior tyrosine kinase inhibitors. Here, we aimed to demonstrate similarity in efficacy/safety of asciminib 80 mg once daily (q.d.) versus 40 mg twice daily (b.i.d.) in patients with CML-CP without T315I mutation and support the use of the 200-mg b.i.d. dosage in patients harboring T315I, using model-informed drug development. METHODS: Data were collected from 199 patients in the phase I (NCT02081378; 10-200 mg b.i.d. or 10-400 mg q.d.) and 154 patients in the phase III (NCT03106779; 40 mg b.i.d.) studies. Evaluations were based on population pharmacokinetics (PopPK) and exposure-response (efficacy/safety) analyses. RESULTS: PopPK showed comparable exposure (area under the curve, AUC0-24h) for 40 mg b.i.d. and 80 mg q.d. (12,638 vs 12,646 ng*h/mL); average maximum and minimum plasma concentrations for 80 mg q.d. were 1.61- and 0.72-fold those of 40 mg b.i.d., respectively. Exposure-response analyses predicted similar major molecular response rates for 40 mg b.i.d. and 80 mg q.d. (Week 24: 27.6% vs 24.8%; Week 48: 32.3% vs 30.6%). Results also established adequacy of 200 mg b.i.d. in patients with T315I mutation (Week 24: 20.7%; Week 48: 23.7%), along with a similar safety profile for all dose regimens. CONCLUSIONS: Similarity between 40 mg b.i.d. and 80 mg q.d. regimens was investigated, demonstrating similar and substantial efficacy with well-tolerated safety in patients without T315I mutation. The 200-mg b.i.d. dose was deemed safe and effective for patients with T315I mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAdultAgedPhiladelphia ChromosomeFusion Proteins, bcr-ablDose-Response Relationship, DrugAntineoplastic AgentsYoung AdultAged, 80 and overArea Under CurveNiacinamidePyrazoles

Substanzen

asciminibProtein Kinase InhibitorsFusion Proteins, bcr-ablAntineoplastic AgentsNiacinamidePyrazoles

Autor:innen und Institutionen

  • Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA. francois_pierre.combes@novartis.com.
  • Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
  • Novartis Pharmaceuticals Corporation, Basel, Switzerland.
  • Novartis Healthcare Pvt Ltd, Hyderabad, India.
  • Novartis Institute of Biomedical Research, Basel, Switzerland.

ORCID-Profile: Francois Pierre Combes

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Combes, F. P., Sy, S. K. B., Li, Y. F., Lorenzo, S., Dasgupta, K., Kapoor, S., Hoch, M., & Ho, Y. Y. (2024). Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01411-1

Vancouver

Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, et al. Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01411-1

BibTeX
@article{Combes2024,
  author = {Combes, Francois Pierre and Sy, Sherwin K B and Li, Ying Fei and Lorenzo, Sebastien and Dasgupta, Kohinoor and Kapoor, Shruti and Hoch, Matthias and Ho, Yu-Yun},
  title = {Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01411-1}
}
Kostenlos starten →